Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

ClinicalTrials.gov ID: NCT01866930

Public ClinicalTrials.gov record NCT01866930. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1

Study identification

NCT ID: NCT01866930
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 453 participants

Conditions and interventions

Conditions

Chronic Hepatitis C Infection

Interventions

Pegylated Interferon Lambda-1a Biological
Daclatasvir (DCV) Drug
Ribasphere (RBV) Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 10, 2013
Primary completion: Aug 26, 2015
Completion: Aug 26, 2015
Last update posted: Jun 12, 2023

2013 – 2015

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Inland Empire Liver Foundation	Rialto	California	92377	—
University Of California San Francisco	San Francisco	California	94110	—
Kaiser Permanente Medical Center	San Francisco	California	94118	—
University Of Colorado Denver & Hospital	Aurora	Colorado	80045	—
University Of Colorado Denver	Aurora	Colorado	80045	—
Yale University	New Haven	Connecticut	06510	—
Orlando Va Medical Center	Orlando	Florida	32803	—
Emory Hospital Midtown Infectious Disease Clinic	Atlanta	Georgia	30308	—
Emory University	Atlanta	Georgia	30308	—
Mercy Medical Center	Baltimore	Maryland	21202	—
Duke Clinical Research Institute	Durham	North Carolina	27710	—
Lehigh Valley Health Network	Allentown	Pennsylvania	18102	—
Ut Southwestern Medical Center	Dallas	Texas	75235	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01866930, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 12, 2023 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01866930 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →